組織蛋白酶L(CTSL)重組蛋白
Recombinant Cathepsin L (CTSL)
CTSL1; CATL; CTS-L; MEP; Cathepsin L1; Major excreted protein
- 編號(hào)RPA306Po01
- 物種Sus scrofa; Porcine (Pig,豬) 相同的名稱,不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位溶酶體
- 預(yù)測分子量48.7kDa
- 實(shí)際分子量49kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Pro115~Gly288 with N-terminal His and GST Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)6.0
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1176 ¥ 2940 ¥ 5880 ¥ 17640 ¥ 44100
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Sus scrofa; Porcine (Pig,豬) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA306Po01 | 組織蛋白酶L(CTSL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA306Po01 | 組織蛋白酶L(CTSL)多克隆抗體 | WB; IHC; ICC; IP. |
LAA306Po81 | 組織蛋白酶L(CTSL)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
LAA306Po71 | 組織蛋白酶L(CTSL)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Hypertension | Identification of Cathepsin L as a Potential Sex-Specific Biomarker for Renal Damage. [Ahajournals: source] |
The Journal of International Medical Research | Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease [Ingenta: art00021] |
Atherosclerosis.? | Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery [Pubmed:24534452] |
International Journal of Molecular Sciences | A New Analytical Method for Determination of Cathepsin L Based on the Surface Plasmon Resonance Imaging Biosensor [Pubmed: 31052424] |
EMBO Molecular Medicine | Immune‐mediated ECM depletion improves tumour perfusion and payload delivery [Pubmed: 31709774] |
Cardiovasc Res | Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size [34132807] |
留言咨詢